PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31322196-8 2019 S100A8 and S100A9 induced translocation of NF-kappaB in a time-dependent manner, and the activation of NF-kappaB was inhibited by TLR4i, rottlerin, PD98059 and SB203580. SB 203580 160-168 nuclear factor kappa B subunit 1 Homo sapiens 43-52 34025070-16 2021 Moreover, SB203580 significantly reduced the pulmonary P-p38, NFkappaB, P-signal transducer and activator of transcription-3 and Myd88 levels but increased the IkappaB and HO-1 levels. SB 203580 10-18 nuclear factor kappa B subunit 1 Homo sapiens 62-70 31322196-8 2019 S100A8 and S100A9 induced translocation of NF-kappaB in a time-dependent manner, and the activation of NF-kappaB was inhibited by TLR4i, rottlerin, PD98059 and SB203580. SB 203580 160-168 nuclear factor kappa B subunit 1 Homo sapiens 103-112 30022772-8 2018 GSK1016790A-induced inhibitor of kappa B-alpha (IkappaBalpha) decomposition, which causes NF-kappaB activation was suppressed by NF157 and SB203580, and gamma-irradiation-induced IkappaBalpha decomposition was suppressed by TRPV4 channel inhibitors. SB 203580 139-147 nuclear factor kappa B subunit 1 Homo sapiens 90-99 31472052-13 2019 However, treatment with gentiopicrin, and p38MAPK/NF-kappaB pathway inhibitors (SB203580 and BAY11-7082) significantly reduced the levels of these inflammatory factors compared with TNF-alpha group (p < 0.05). SB 203580 80-88 nuclear factor kappa B subunit 1 Homo sapiens 50-59 30073566-6 2018 Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2. SB 203580 193-201 nuclear factor kappa B subunit 1 Homo sapiens 14-23 30801954-6 2019 Our results demonstrated NF-kappaB activation and protein levels of MMP-9, XIAP, VEGF, and Cyclin-D1 were significantly reduced by NF-kappaB (QNZ), ERK (PD98059), and P38 (SB203580) inhibitors. SB 203580 172-180 nuclear factor kappa B subunit 1 Homo sapiens 25-34 30801954-6 2019 Our results demonstrated NF-kappaB activation and protein levels of MMP-9, XIAP, VEGF, and Cyclin-D1 were significantly reduced by NF-kappaB (QNZ), ERK (PD98059), and P38 (SB203580) inhibitors. SB 203580 172-180 nuclear factor kappa B subunit 1 Homo sapiens 131-140 30320396-9 2018 SB203580 significantly decreased the expression of NF-kappaB in MKN-45 cells infected with H. pylori. SB 203580 0-8 nuclear factor kappa B subunit 1 Homo sapiens 51-60 26649771-6 2015 We also found that SB203580 and Bay11-7082, inhibitors of p38MAPK and NF-kappaB, respectively, suppressed LTA-induced DEFB131 expression. SB 203580 19-27 nuclear factor kappa B subunit 1 Homo sapiens 70-79 28432555-5 2017 Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes. SB 203580 49-57 nuclear factor kappa B subunit 1 Homo sapiens 138-147 26881015-7 2016 U0126 and SB203580 both counteracted the activation of NF-kappaB, whereas the phosphorylation of ERK1/2 and p38(MAPK) was not blocked by SN50. SB 203580 10-18 nuclear factor kappa B subunit 1 Homo sapiens 55-64 28749049-8 2018 When hPDLSCs were treated with the inhibitors of NF-kappaB and MAPK pathways (U0126, SP600125, SB203580, and BMS345541), the effects of MTA on the differentiation of hPDLSCs were suppressed. SB 203580 95-103 nuclear factor kappa B subunit 1 Homo sapiens 49-58 28455228-6 2017 Besides, SP600125 and SB203580 also reversed the inactivation of NF-kappab and Stat3. SB 203580 22-30 nuclear factor kappa B subunit 1 Homo sapiens 65-74 30090349-10 2016 Moreover, the NF-kappaB inhibitor (PDTC), the ERK inhibitor (PD98059), the JNK inhibitor (SP600125), and the p38 MAPK inhibitor (SB203580) markedly attenuated the growth of these cells. SB 203580 129-137 nuclear factor kappa B subunit 1 Homo sapiens 14-23 26884859-9 2015 Furthermore, we clarified that nuclear NF-kappaB and P38 MAPK pathways play pivotal roles in regulating U937s" migration and MMP9 expressions using PDTC and SB203580, which were specific inhibitors of NF-kappaB and p38 MAPK pathways. SB 203580 157-165 nuclear factor kappa B subunit 1 Homo sapiens 39-48 26884859-9 2015 Furthermore, we clarified that nuclear NF-kappaB and P38 MAPK pathways play pivotal roles in regulating U937s" migration and MMP9 expressions using PDTC and SB203580, which were specific inhibitors of NF-kappaB and p38 MAPK pathways. SB 203580 157-165 nuclear factor kappa B subunit 1 Homo sapiens 201-210 25811965-8 2015 However, the addition of p38 MAPK inhibitor SB203580 significantly reduced the activation of NF-kappaB; meanwhile, baicalein was shown to exert an inhibitory effect on p38 activation. SB 203580 44-52 nuclear factor kappa B subunit 1 Homo sapiens 93-102 25845399-7 2015 Furthermore, phosphorylation of the p38 protein and nuclear factor (NF)-kappaB activity in the PC3 cells were enhanced by LPS and further inhibited with sesamin, SB203580 pretreatment or p38-siRNA transfection, respectively. SB 203580 162-170 nuclear factor kappa B subunit 1 Homo sapiens 52-78 25250801-9 2014 In addition, treatment of cervical cancer cells with the pharmacological p38/NF-kappaB signal pathway inhibitors, SB203580 and PDTC, potently restored the roles of invasion and upregulation of MMPs induced by IL-17A. SB 203580 114-122 nuclear factor kappa B subunit 1 Homo sapiens 77-86 23467542-6 2013 Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB. SB 203580 44-52 nuclear factor kappa B subunit 1 Homo sapiens 128-137 24126532-11 2014 Combined pretreatment with an inhibitor of NF-kappaB (BAY11-7082) and SB203580 was more efficient in inhibiting the ability of HbR to induce IL-8 production than pretreatment with either BAY11-7082 or SB203580 alone. SB 203580 201-209 nuclear factor kappa B subunit 1 Homo sapiens 43-52 23684722-11 2013 Additionally, inhibition of autophagy by the specific autophagic inhibitor 3MA or blocking the p38-NF-kappaB pathway with p38 inhibitor SB203580 or NF-kappaB inhibitor PDTC obviously promoted physalin A-induced apoptosis. SB 203580 136-144 nuclear factor kappa B subunit 1 Homo sapiens 99-108 23467542-6 2013 Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB. SB 203580 62-70 nuclear factor kappa B subunit 1 Homo sapiens 128-137 23456298-8 2013 The phosphorylation of p38 MAPK was not affected by the NF-kappaB inhibitor Bay whereas activation of NF-kappaB was blocked by p38 MAPK inhibitor SB203580, indicating that S100A8/A9-induced NF-kappaB activation is mediated by phosphorylation of p38 MAPK. SB 203580 146-154 nuclear factor kappa B subunit 1 Homo sapiens 102-111 23456298-8 2013 The phosphorylation of p38 MAPK was not affected by the NF-kappaB inhibitor Bay whereas activation of NF-kappaB was blocked by p38 MAPK inhibitor SB203580, indicating that S100A8/A9-induced NF-kappaB activation is mediated by phosphorylation of p38 MAPK. SB 203580 146-154 nuclear factor kappa B subunit 1 Homo sapiens 102-111 23456298-9 2013 S100A8/A9-induced cell migration and invasion was inhibited by SB203580 and Bay, suggesting that activation of p38 MAPK and NF-kappaB is involved in the S100A8/A9 induced cell migration and invasion. SB 203580 63-71 nuclear factor kappa B subunit 1 Homo sapiens 124-133 22079475-6 2012 Additionally, the treatment of inhibitors specific for p38 MAPK (SB203580) or PI3K (wortmannin) to cells could result in a reduced expression of NF-kappaB and MMP-9 expression, concomitantly with an inhibition on cell metastasis. SB 203580 65-73 nuclear factor kappa B subunit 1 Homo sapiens 145-154 22505709-11 2012 Inhibition of p38MAPK and NF-kappaB activity by SB203580 and/or CAPE reduced Fas expression and apoptosis in salivary epithelial cells, establishing p38MAPK and NF-kappaB as proapoptotic factors in this context. SB 203580 48-56 nuclear factor kappa B subunit 1 Homo sapiens 26-35 22301607-9 2012 Furthermore, SB203580 (p38 inhibitor) but not PD98059 (ERK1/2 inhibitor) blocked LPS-induced NF-kappaB activation; however, both inhibitors significantly suppressed IL-6/TNF-alpha mRNA and protein expression. SB 203580 13-21 nuclear factor kappa B subunit 1 Homo sapiens 93-102 22853328-7 2012 Inhibition of nuclear factor (NF)-kappa B (kappaB) by helenalin and p38 mitogen-activated protein kinase (MAPK) by SB203580 prevented production of IL-12 p40, IL-12 p70, and IL-10. SB 203580 115-123 nuclear factor kappa B subunit 1 Homo sapiens 14-41 22226621-8 2012 What is more, the p38 inhibitor (SB203580) but not ERK1/2 inhibitor (PD98059) blocked LPS-induce NF-kappaB transactivation and ICAM-1 expression, which demonstrates that RhoA mediates LPS-induced NF-kappaB transactivation and ICAM-1 expression dominantly through p38 but not ERK1/2 activation. SB 203580 33-41 nuclear factor kappa B subunit 1 Homo sapiens 97-106 23281704-5 2012 Treatment of the cells with p38 inhibitor SB203580 and NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) showed that p38 functioned upstream of NF-kappaB, while augmented apoptosis and cell cycle arrest were induced in response to NCTD with NF-kappaB activation. SB 203580 42-50 nuclear factor kappa B subunit 1 Homo sapiens 149-158 22799384-6 2012 In addition, ERK1/2 and p38 MAPK were shown to play a crucial role in mediating EGF-induced NF-kappaB translocation and phosphorylation of IkappaBalpha when treated with the MAPK inhibitors, PD98059 and SB203580, which resulted in increased MMP-12 expression. SB 203580 203-211 nuclear factor kappa B subunit 1 Homo sapiens 92-101 23281704-5 2012 Treatment of the cells with p38 inhibitor SB203580 and NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) showed that p38 functioned upstream of NF-kappaB, while augmented apoptosis and cell cycle arrest were induced in response to NCTD with NF-kappaB activation. SB 203580 42-50 nuclear factor kappa B subunit 1 Homo sapiens 149-158 22041445-18 2011 (4) The p38MAPK inhibitor SB203580 significantly reduced the expression of EGF-induced MMP-9 (0.645+-0.270 vs. 1.476+-0.452, P<0.05) and NF-kappaB (0.530+-0.026 vs. 0.959+-0.017, P<0.05). SB 203580 26-34 nuclear factor kappa B subunit 1 Homo sapiens 140-149 18710428-6 2009 Inhibition studies using SB203580 (inhibitor of p38MAPK), U0126 (inhibitor of mitogen-activated or extracellular signal-regulated protein kinase 1/2) and MG132 (inhibitor of NF-kappaB) showed that the phosphorylation of Erk1/2 and p38MAPK with activation of NF-kappaB was closely related to MMP-9 upregulation in both cell lines. SB 203580 25-33 nuclear factor kappa B subunit 1 Homo sapiens 174-183 20231411-7 2010 Inhibition of p38 mitogen-activated protein kinase (MAPK) using SB203580 and small interfering RNA (siRNA) transfection resulted in a significant reduction in BFT-induced I kappaB kinase (IKK)/NF-kappaB activation and hBD-2 expression. SB 203580 64-72 nuclear factor kappa B subunit 1 Homo sapiens 193-202 19931737-8 2009 The p38 inhibitor SB203580, by blocking nuclear factor-kappaB (NF-kappaB) activation, prevented both the transcriptional and translational regulation of radiation-induced IL-6 expression. SB 203580 18-26 nuclear factor kappa B subunit 1 Homo sapiens 63-72 19558798-6 2009 NO production induced by MAPKs and NF-kappaB was similarly reduced by inhibitors of ERK (PD98059), p38 (SB203580), NF-kappaB (N-acetylcysteine), and NSA9. SB 203580 104-112 nuclear factor kappa B subunit 1 Homo sapiens 35-44 18710428-6 2009 Inhibition studies using SB203580 (inhibitor of p38MAPK), U0126 (inhibitor of mitogen-activated or extracellular signal-regulated protein kinase 1/2) and MG132 (inhibitor of NF-kappaB) showed that the phosphorylation of Erk1/2 and p38MAPK with activation of NF-kappaB was closely related to MMP-9 upregulation in both cell lines. SB 203580 25-33 nuclear factor kappa B subunit 1 Homo sapiens 258-267 18425744-9 2008 Specific inhibitors of p38 kinase, SB203580, significantly inhibited NFkappaB activation and increased the cytotoxicity effect in cells exposed to gliotoxin combined with irradiation. SB 203580 35-43 nuclear factor kappa B subunit 1 Homo sapiens 69-77 18812223-8 2008 Treatment of the repetitively stressed cells concurrently with Resveratrol or SB203580, a p38MAPK inhibitor, robustly blocked activation of p38MAPK, NFkappaB transcriptional activity, phosphorylation and nuclear localization of p65, and Akt phosphorylation. SB 203580 78-86 nuclear factor kappa B subunit 1 Homo sapiens 149-157 18328478-8 2008 Further, western blot analysis that showed SB203580 administration can inhibit the activation of NF-kappaB, which was associated with the inhibition of IkappaBalpha degradation in cytoplasm. SB 203580 43-51 nuclear factor kappa B subunit 1 Homo sapiens 97-106 18276112-8 2008 US-mediated an increase of IKKalpha/beta activity, kappaB-luciferase activity and p65 and p50 binding to the NF-kappaB element was inhibited by araA, SB203580 and LKB1 siRNA. SB 203580 150-158 nuclear factor kappa B subunit 1 Homo sapiens 90-93 18357389-9 2008 The transactivation of TNF-alpha-stimulated NF-kappaB, AP-1 and Sp-1 were inhibited by U0126 and SB203580 treatment. SB 203580 97-105 nuclear factor kappa B subunit 1 Homo sapiens 44-53 18358890-4 2008 LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein. SB 203580 226-234 nuclear factor kappa B subunit 1 Homo sapiens 32-54 18358890-4 2008 LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein. SB 203580 226-234 nuclear factor kappa B subunit 1 Homo sapiens 56-65 18324518-5 2008 After interruption of p38 and nuclear factor-kappaB (NF-kappaB) by pre-treatment with SB203580 and PDTC, iNOS expression, NO synthesis and cell damage were all significantly blocked. SB 203580 86-94 nuclear factor kappa B subunit 1 Homo sapiens 53-62 17636246-7 2007 In addition, p38 MAPK and NF-kappaB were independently activated by NiSO(4) since SB203580 did not inhibit NF-kappaB activation by NiSO(4). SB 203580 82-90 nuclear factor kappa B subunit 1 Homo sapiens 26-35 17911635-9 2007 Adiponectin-mediated an increase of IKK alpha/beta activity, kappaB-luciferase activity, and p65 and p50 binding to the NF-kappaB element and was inhibited by compound C, SB203580 and AdipoR1 small interference RNA. SB 203580 171-179 nuclear factor kappa B subunit 1 Homo sapiens 101-104 16498455-6 2006 TAK1-DN, MKK6-DN, and SB203580, but not MKK3-DN, also suppressed RANKL stimulation of NF-kappaB transcription activity in a manner dependent on p65 phosphorylation on Ser-536. SB 203580 22-30 nuclear factor kappa B subunit 1 Homo sapiens 86-95 17196679-5 2007 Treatment of the cells concurrently with SB203580, a specific p38MAPK inhibitor, robustly blocked activation of NFkappaB transcriptional activity, phosphorylation of p65, and IKK but only partially blocked Akt phosphorylation. SB 203580 41-49 nuclear factor kappa B subunit 1 Homo sapiens 112-120 17251521-6 2007 PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion. SB 203580 10-19 nuclear factor kappa B subunit 1 Homo sapiens 87-108 17251521-6 2007 PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion. SB 203580 10-19 nuclear factor kappa B subunit 1 Homo sapiens 110-119 17464346-10 2007 The increased secretion of TNF-alpha and sICAM-1 and the increased activity of NF-kappaB by ADMA were altered by SB203580 (5 micromol/L) or PD98059 (20 micromol/L), but not by LY294002 (20 micromol/L). SB 203580 113-121 nuclear factor kappa B subunit 1 Homo sapiens 79-88 15378016-6 2004 Interestingly, re-expression of E-cadherin-blocked p38 MAPK activity and the p38 MAPK inhibitors SB203580 and SB202190 almost completely prevented NFkappaB activation in melanoma cells. SB 203580 97-105 nuclear factor kappa B subunit 1 Homo sapiens 147-155 16385547-10 2006 NF-kappaB activation and IkappaBalpha degradation induced by aPL were inhibited by the NF-kappaB inhibitor SN50 and the p38 MAP kinase inhibitor SB203580, thus suggesting crosstalk between these pathways. SB 203580 145-153 nuclear factor kappa B subunit 1 Homo sapiens 0-9 16028365-6 2005 Pretreatment with the p38 MAP kinase inhibitor, SB203580 and the ERK1/2 inhibitor, PD98059, prevented t-BHP-induced increases in p65 translocation, NF-kappaB luciferase activity, and phospho-IKKalpha/beta. SB 203580 48-56 nuclear factor kappa B subunit 1 Homo sapiens 148-157 14563684-5 2003 In reporter gene assays, IL-1beta time-dependently increased the promoter activity, which was abolished by either pre-treatment with the MAP kinase inhibitors PD98059 (MEK) and SB203580 (p38), pre-treatment with the NF-kappaB inhibitor PDTC, or deletion of the kappaB site. SB 203580 177-185 nuclear factor kappa B subunit 1 Homo sapiens 216-225 15147892-5 2004 Pretreatment with ERK inhibitor PD98059, and p38 MAPK inhibitor SB203580, attenuated the induction of p65 translocation, IkappaB phosphorylation, and NF-kappaB luciferase activity. SB 203580 64-72 nuclear factor kappa B subunit 1 Homo sapiens 150-159 14736878-8 2004 Concerning the signal transduction, a mitogen-activated protein kinase kinase inhibitor (PD98089) and a nuclear factor (NF)-kappaB inhibitor (SN50) suppressed the up-regulation of MIF mRNA in response to thrombin, FXa, and PAR-2 agonist stimulation, whereas a p38 inhibitor (SB203580) had little effect. SB 203580 275-283 nuclear factor kappa B subunit 1 Homo sapiens 104-130 15289440-7 2004 An analysis of the molecular basis of NF-kappaB activation revealed that Rip-like interacting caspase-like apoptosis-regulatory protein kinase (RICK), a key component of a pathway leading to NF-kappaB induction, is also strongly inhibited by SB203580. SB 203580 242-250 nuclear factor kappa B subunit 1 Homo sapiens 38-47 15289440-7 2004 An analysis of the molecular basis of NF-kappaB activation revealed that Rip-like interacting caspase-like apoptosis-regulatory protein kinase (RICK), a key component of a pathway leading to NF-kappaB induction, is also strongly inhibited by SB203580. SB 203580 242-250 nuclear factor kappa B subunit 1 Homo sapiens 191-200 14568957-11 2003 SB203580 also inhibited LPS-induced production of IL-1beta, IL-10, and TNF-alpha; enhanced IL-12 production; and recovered the activity of ERK and NF-kappaB. SB 203580 0-8 nuclear factor kappa B subunit 1 Homo sapiens 147-156 12853969-6 2003 IL-6 activation by TGF-beta1 was accompanied by nuclear translocation of NF-kappaB, which was blocked by the p38 inhibitors SB202190 and SB203580 or by IkappaBalphaDeltaN transfection, indicating the crucial role for the p38-NF-kappaB signaling in TGF-beta1 induction of IL-6. SB 203580 137-145 nuclear factor kappa B subunit 1 Homo sapiens 73-82 12438537-5 2002 Inhibition of p38 mitogen-activated protein kinase (MAPK) with SB203580 substantially inhibited Con A- or IL-1beta-induced DNA binding activity of NF-kappaB, whereas ZnTMPyP inhibited the activation of p38 MAPK. SB 203580 63-71 nuclear factor kappa B subunit 1 Homo sapiens 147-156 12471041-13 2003 Interestingly, the HRG-beta 1-induced NF-kappa B activation cascade was also effectively blocked by SB203580 treatment or p38AF transfection. SB 203580 100-108 nuclear factor kappa B subunit 1 Homo sapiens 38-48 12403788-12 2003 SB203580 restored AA-induced NF-kappaB translocation, which may contribute to protection against toxicity. SB 203580 0-8 nuclear factor kappa B subunit 1 Homo sapiens 29-38 11708812-6 2001 The p38 MAPK inhibitor, SB203580, and a dominant negative form of p38 MAPK decreased the CD40 activation of the C epsilon promoter by reducing the ability of CD40 to increase the transactivation potential of NF kappa B. SB 203580 24-32 nuclear factor kappa B subunit 1 Homo sapiens 208-218 12117921-5 2002 TNF-alpha and IL-6 mRNA expression by PBLs was inhibited with SB 203580 (a p38 mitogen-activated protein kinase [MAPK] inhibitor), MG-132 (a proteasome inhibitor), and SN-50 (an NF-kappaB inhibitor). SB 203580 62-71 nuclear factor kappa B subunit 1 Homo sapiens 178-187 11120850-8 2000 Inhibition of TNF-driven IKK activation was mediated by p38 mitogen-activated protein kinase, because treatment of cells with vitamin C led to a rapid and sustained activation of p38, and the specific p38 inhibitor SB203580 reversed the inhibitory effect of vitamin C on IKK activity, I-kappaBalpha phosphorylation, and NF-kappaB activation. SB 203580 215-223 nuclear factor kappa B subunit 1 Homo sapiens 320-329 11432978-6 2001 Pretreatment with PD098059 and/or SB203580 decreased nitric oxide (NO) production and nuclear factor-kappa B (NF-kappaB) activation. SB 203580 34-42 nuclear factor kappa B subunit 1 Homo sapiens 86-108 11432978-6 2001 Pretreatment with PD098059 and/or SB203580 decreased nitric oxide (NO) production and nuclear factor-kappa B (NF-kappaB) activation. SB 203580 34-42 nuclear factor kappa B subunit 1 Homo sapiens 110-119 11606413-6 2001 Pretreatment of HeLa cells with SB 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (MAPK), abrogated the ability of indomethacin to inhibit IR-induced activation of NF-kappaB and diminished the indomethacin radiosensitizing effect. SB 203580 32-41 nuclear factor kappa B subunit 1 Homo sapiens 220-229 11257311-5 2001 ANP inhibited the IFN-gamma-induced p38 MAP kinase activation, and ANP and SB203580 inhibited NF-kappaB activation. SB 203580 75-83 nuclear factor kappa B subunit 1 Homo sapiens 94-103 10783388-6 2000 However, SB203580 depressed the expression of NF-kappaB-dependent genes, as monitored by a kappaB-driven reporter gene. SB 203580 9-17 nuclear factor kappa B subunit 1 Homo sapiens 46-55 10823821-6 2000 TRAIL-, anti-APO-1-, and FADD-(80-208)-initiated gene induction was blocked by a dominant-negative mutant of TRAF2 or the p38 kinase inhibitor SB203580, similar to tumor necrosis factor receptor-1-induced NF-kappaB activation. SB 203580 143-151 nuclear factor kappa B subunit 1 Homo sapiens 205-214 10960075-0 2000 The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. SB 203580 29-37 nuclear factor kappa B subunit 1 Homo sapiens 47-69 10960075-4 2000 In fact, 5 and 10 microM SB203580 enhanced rather than inhibited NF-kappaB-mediated promoter activity by 2 fold, which was independent of phosphorylation of the p65 subunit. SB 203580 25-33 nuclear factor kappa B subunit 1 Homo sapiens 65-74 10960075-5 2000 The SB203580-mediated increase in NF-kappaB transcriptional activity was associated with enhanced phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK), but not p38 kinase. SB 203580 4-12 nuclear factor kappa B subunit 1 Homo sapiens 34-43 10960075-6 2000 Overexpression of kinase-deficient mutants belonging to the ERK1/2, JNK, and p38 pathways showed that only dominant-negative Raf-1 abrogated SB203580-enhanced NF-kappaB activity. SB 203580 141-149 nuclear factor kappa B subunit 1 Homo sapiens 159-168 10960075-7 2000 This would implicate the involvement of the ERK1/2 pathway in the enhancing effects of SB203580 on NF-kappaB-mediated gene transcription. SB 203580 87-95 nuclear factor kappa B subunit 1 Homo sapiens 99-108 10960075-9 2000 SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-kappaB transcriptional activity. SB 203580 0-8 nuclear factor kappa B subunit 1 Homo sapiens 89-98 10447723-5 1999 LPS activation of nuclear factor-kappa B (NF-kappaB), activator protein-1 (AP-1) and p38 MAPK was also inhibited by SB 203580. SB 203580 116-125 nuclear factor kappa B subunit 1 Homo sapiens 18-40 10447723-5 1999 LPS activation of nuclear factor-kappa B (NF-kappaB), activator protein-1 (AP-1) and p38 MAPK was also inhibited by SB 203580. SB 203580 116-125 nuclear factor kappa B subunit 1 Homo sapiens 42-51 9759836-4 1998 SB203580 also significantly reduced expression of a reporter gene driven by a minimal promoter containing four NF-kappaB elements, indicating a requirement for the p38 MAPK pathway in CD40-induced NF-kappaB activation. SB 203580 0-8 nuclear factor kappa B subunit 1 Homo sapiens 111-120 10051531-11 1999 SB 203580 but not PD 98059 inhibited the LPS-induced stimulation of NF-kappaB DNA-protein binding. SB 203580 0-9 nuclear factor kappa B subunit 1 Homo sapiens 68-77 9759836-4 1998 SB203580 also significantly reduced expression of a reporter gene driven by a minimal promoter containing four NF-kappaB elements, indicating a requirement for the p38 MAPK pathway in CD40-induced NF-kappaB activation. SB 203580 0-8 nuclear factor kappa B subunit 1 Homo sapiens 197-206 8617238-6 1996 Under the same conditions, SB203580 also completely inhibited TNF-induced synthesis of interleukin (IL)-6 and expression of a reporter gene that was driven by a minimal promoter containing two NF-Kappa B elements. SB 203580 27-35 nuclear factor kappa B subunit 1 Homo sapiens 193-203 9452444-6 1998 We observed that the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 was able to repress TNF-stimulated expression of the IL-6 gene, as well as of a kappaB-dependent reporter gene construct, without affecting the levels of NF-kappaB binding to DNA. SB 203580 75-83 nuclear factor kappa B subunit 1 Homo sapiens 238-247 34303041-5 2021 Mechanistically, the process described above is mediated through the NF-kappaB and p38 MAPK signaling pathways, which can be abated by corresponding inhibitors, such as BAY11-7082 and SB203580, respectively. SB 203580 184-192 nuclear factor kappa B subunit 1 Homo sapiens 69-78 35056795-7 2022 This study also investigated the role of p38 and NF-kappaB in cell signaling events and found that SB203580 (an inhibitor of p38) markedly reduced p38, IKK, and p65 phosphorylation and reversed IkappaBalpha degradation as well as p65 activation in a confocal microscope, whereas BAY11-7082 had no effects in p38 phosphorylation. SB 203580 99-107 nuclear factor kappa B subunit 1 Homo sapiens 49-58